CorMedix's DefenCath cuts infection risk by 71% for dialysis patients. Despite its potential, CMD stock is fairly priced post ...
CorMedix Inc.'s DefenCath reduces catheter infections by 71%, but the limited market potential challenges long-term adoption.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback